ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ARASENS post hoc sensitivity analysis data presented at ASCO GU 2024 support primary OS analysis and demonstrate that darolutamide + ADT + docetaxel is an effective, well-tolerated SoC for mHSPC.